<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434354</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01615</org_study_id>
    <nct_id>NCT02434354</nct_id>
  </id_info>
  <brief_title>A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma</brief_title>
  <official_title>A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to evaluate the safety, tolerability and adverse event&#xD;
      profile of pembrolizumab in subjects who have high risk melanoma before and after their&#xD;
      standard of care surgical resection, and to collect tumor tissue from subjects before and&#xD;
      after receipt of pembrolizumab to look at how the experimental drug interacts with tumor&#xD;
      tissue. Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete&#xD;
      resection and then a year of adjuvant pembrolizumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      detailed description listed above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants (%) With CTCAE Graded Adverse Events</measure>
    <time_frame>within 30 days of final study treatment</time_frame>
    <description>Safety as defined by 1) all grade 3/4 adverse events and 2) any grade adverse event that occurred in&gt;5% of patients. Toxicities are graded using CTCAE Version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>until death, withdrawal of consent of end of the study. as such, we have not reached the median DFS and will report at the end of the study</time_frame>
    <description>To evaluate disease free survival (DFS) in patients receiving Pembrolizumab as adjuvant therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>neo-adjuvant/adjuvant pembrolizaumab 200 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab</description>
    <arm_group_label>neo-adjuvant/adjuvant pembrolizaumab 200 mg IV</arm_group_label>
    <other_name>keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject must have clinical stage III or resectable stage IV MEL. Subject's may not&#xD;
             have a diagnosis of uveal or mucosal melanoma.&#xD;
&#xD;
          2. The subject must be expected to have an adequate amount of tumor burden to yield 2-4&#xD;
             pre-operative research core biopsy (14-gauge needle) specimens or the equivalent&#xD;
             amount of tissue (4-6 mm punch biopsy), in addition, to the tissue required for&#xD;
             diagnostic purposes.&#xD;
&#xD;
          3. The subject must be expected to have an adequate amount of residual tumor after their&#xD;
             pre-operative research tumor tissue collection, such that their operative research&#xD;
             tumor collection will also yield at least 4-6 research core biopsy specimens or the&#xD;
             equivalent amount of tissue&#xD;
&#xD;
          4. The subject must be willing to undergo the two paired tumor tissue biopsy procedures&#xD;
             to obtain samples for biomarker analysis. Tissue obtained must not be previously&#xD;
             irradiated.&#xD;
&#xD;
          5. Either the subject or the subject's legal representative must be willing and able to&#xD;
             provide written informed consent for the trial.&#xD;
&#xD;
          6. The subject must be ≥ 18 years of age on day of signing informed consent.&#xD;
&#xD;
          7. The subject must have a performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          8. The subject must demonstrate adequate organ function as defined in Table 1, all&#xD;
             screening labs must be performed within 10 days of treatment initiation.&#xD;
&#xD;
             Table 1 Adequate Organ Function Laboratory Values System Laboratory Value&#xD;
             Hematological Absolute neutrophil count (ANC)&#xD;
&#xD;
               -  1500/mcL Platelets&#xD;
&#xD;
               -  100,000/ mcL Hemoglobin&#xD;
&#xD;
               -  9 g/dL or ≥5.6 mmol/L Renal Serum creatinine OR Measured or calculated creatinine&#xD;
                  clearance (GFR can also be used in place of creatinine or CrCl)&#xD;
&#xD;
                  ≤1.5 X upper limit of normal (ULN) OR&#xD;
&#xD;
               -  50 mL/min for subject with creatinine levels &gt; 1.5 X institutional ULN UPCC#&#xD;
                  01615: Tissue Collection Study of Pembrolizumab in Advanced Melanoma Version&#xD;
                  Date: 12/30/2014 Page 10 Hepatic Serum total bilirubin&#xD;
&#xD;
                    -  1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels&#xD;
                       &gt; 1.5 ULN AST (SGOT) and ALT (SGPT)&#xD;
&#xD;
                    -  2.5 X ULN OR&#xD;
&#xD;
                    -  5 X ULN for subjects with liver metastases Coagulation International&#xD;
                       Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial&#xD;
                       Thromboplastin Time (aPTT)&#xD;
&#xD;
                    -  1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or&#xD;
                       PTT is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
                    -  1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or&#xD;
                       PTT is within therapeutic range of intended use of anticoagulants&#xD;
                       aCreatinine clearance should be calculated per institutional standard.&#xD;
&#xD;
          9. Female subject's of childbearing potential must have a negative serum pregnancy test&#xD;
             within 72 hours prior to receiving the first dose of study medication.&#xD;
&#xD;
         10. The subject must be willing to use protocol defined method(s) of contraception:&#xD;
&#xD;
        Female subjects of childbearing potential must be willing to use 2 methods of&#xD;
        contraception, or abstain from heterosexual sexual intercourse for two weeks before the&#xD;
        time of the first dose of study medication, while on study, through 120 days after the last&#xD;
        dose of study medication.&#xD;
&#xD;
        Female subject's of childbearing potential are defined as those women who have not been&#xD;
        surgically sterilized or have not been free from menses for &gt; 1 year.&#xD;
&#xD;
        Male subjects must agree to use an adequate method of contraception starting with the first&#xD;
        dose of study medication, while on study, through 120 days after the last dose of study&#xD;
        medication.&#xD;
&#xD;
        Acceptable forms of birth control include condoms, diaphragms, cervical cap, an&#xD;
        intra-uterine device (IUD), surgical sterility (tubal ligation or a partner that has&#xD;
        undergone a vasectomy), or oral contraceptives, OR the subject must agree to completely&#xD;
        abstain from heterosexual intercourse. Abstinence at certain times of the cycle only, such&#xD;
        as during the days of ovulation, after ovulation and withdrawal are not acceptable methods&#xD;
        of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has unresectable disease; i.e. in the opinion of the surgical oncologist, all&#xD;
             of the subject's melanoma cannot be completely removed with a clear margin.&#xD;
&#xD;
          2. Subject is currently participating in or has participated in a study of an&#xD;
             investigational agent or using an investigational device within 4 weeks of the first&#xD;
             dose of study treatment.&#xD;
&#xD;
          3. Subject has a known hypersensitivity to pembrolizumab or any of its ingredients.&#xD;
&#xD;
          4. Subject has a diagnosis of immunodeficiency or is receiving systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior to enrollment.&#xD;
&#xD;
          5. Subject has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who&#xD;
             has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          6. Subject has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents&#xD;
             (including ipilimumab), interferon, high dose IL-1 or any other antibody or drug&#xD;
             specifically targeting T-cell co-stimulation or checkpoint pathways.&#xD;
&#xD;
          7. Subject has had prior chemotherapy, targeted small molecule therapy, 2 weeks prior to&#xD;
             study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse&#xD;
             events due to a previously administered agent Note: Subjects with ≤ Grade 2 neuropathy&#xD;
             are an exception to this criterion&#xD;
&#xD;
          8. For subject's who have received major surgery, the subject must have recovered&#xD;
             adequately from the toxicity and/or complications from the intervention prior to&#xD;
             starting study therapy.&#xD;
&#xD;
          9. Subject has had radiation therapy to the tumor selected for research collection, or&#xD;
             has had radiation therapy to any site within 4 weeks prior to study Day 1.&#xD;
&#xD;
         10. Subject has received transfusion of blood products (including platelets or red blood&#xD;
             cells) or administration of colony stimulating factors (including G-CSF, GM-CSF or&#xD;
             recombinant erythropoietin) within 4 weeks prior to study Day 1.&#xD;
&#xD;
         11. Subject has a known additional malignancy that is progressing or requires active&#xD;
             treatment.&#xD;
&#xD;
         12. Subject has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
             Note: Subjects with previously treated brain metastases will be eligible to&#xD;
             participate provided they are stable (without evidence of progression by imaging for&#xD;
             at least four weeks prior to the first dose of trial treatment and any neurologic&#xD;
             symptoms have returned to baseline), have no evidence of new or enlarging brain&#xD;
             metastases, and are not using steroids for at least 7 days prior to trial treatment.&#xD;
&#xD;
         13. Subject has an active autoimmune disease requiring systemic treatment within the past&#xD;
             3 months or a documented history of clinically severe autoimmune disease, or a&#xD;
             syndrome that requires systemic steroids or immunosuppressive agents.&#xD;
&#xD;
             Note: Subjects with vitiligo or resolved childhood asthma/atopy are an exception to&#xD;
             this rule. Subjects that require intermittent use of bronchodilators or local steroid&#xD;
             injections will not be excluded from the study. Subjects with hypothyroidism stable on&#xD;
             hormone replacement or Sjorgen's syndrome will not be excluded from the study.&#xD;
&#xD;
         14. Subject has evidence of interstitial lung disease or active, non-infectious&#xD;
             pneumonitis.&#xD;
&#xD;
         15. Subject has an active infection requiring systemic therapy, including active&#xD;
             tuberculosis&#xD;
&#xD;
         16. Subject has a history or current evidence of any condition, therapy, or laboratory&#xD;
             abnormality that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         17. Subject has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         18. Subject is pregnant or breastfeeding, or expecting to conceive or father a child&#xD;
             within the projected duration of the trial participation (from 2 weeks prior to the&#xD;
             first dose of study treatment, while participating on the study and through 120 days&#xD;
             after the last dose of trial treatment).&#xD;
&#xD;
         19. Subject has severe cardiovascular disease, i.e. arrhythmias, requiring chronic&#xD;
             treatment, congestive heart failure (NYHA Class III or IV) or symptomatic ischemic&#xD;
             heart disease.&#xD;
&#xD;
         20. Subject has hepatic decompensation (Child-Pugh score &gt;6 [class B and C]).&#xD;
&#xD;
         21. Subject has uncontrolled thyroid dysfunction&#xD;
&#xD;
         22. Subject has uncontrolled diabetes mellitus&#xD;
&#xD;
         23. Subject has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)&#xD;
             as determined by medical record review.&#xD;
&#xD;
         24. Subject has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV&#xD;
             RNA [qualitative] is detected) as determined by medical record review.&#xD;
&#xD;
         25. Subject has received a live vaccine within 30 days prior to the first dose of trial&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara Mitchell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30804515</url>
    <description>Pubmed link</description>
  </link>
  <results_reference>
    <citation>Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25.</citation>
    <PMID>30804515</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>March 6, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical stage III or resectable stage IV melanoma (MEL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study already published</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02434354/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neo-adjuvant/Adjuvant Pembrolizumab 200mgIV</title>
          <description>Pembrolizumab 200 mg: Subjects received 1 dose of neoadjuvant pembrolizumab, followed by complete resection, and then a year of adjuvant pembrolizumab.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33">Consented</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post Consent Screening</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screen fail</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who were consented and completed post-consent screening</population>
      <group_list>
        <group group_id="B1">
          <title>Neo-adjuvant/Adjuvant Pembrolizumab 200mg IV</title>
          <description>Pembrolizumab 200 mg: Subjects received 1 dose of neoadjuvant pembrolizumab, followed by complete resection, and then a year of adjuvant pembrolizumab.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at Study Entry</title>
          <description>Stage IIIB (at least 1 bulky regional lymph node), IIIC (bulky regional lymph nodes and/or ulcerated primary tumor), Stage IV (distant metastasis)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline LDH</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>cutaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BRAF V600</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Wild Type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PLX4032</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants (%) With CTCAE Graded Adverse Events</title>
        <description>Safety as defined by 1) all grade 3/4 adverse events and 2) any grade adverse event that occurred in&gt;5% of patients. Toxicities are graded using CTCAE Version 4.</description>
        <time_frame>within 30 days of final study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neo-adjuvant/Adjuvant Pembrolizaumab 200 mg IV</title>
            <description>All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year&#xD;
pembrolizumab: 200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (%) With CTCAE Graded Adverse Events</title>
          <description>Safety as defined by 1) all grade 3/4 adverse events and 2) any grade adverse event that occurred in&gt;5% of patients. Toxicities are graded using CTCAE Version 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>To evaluate disease free survival (DFS) in patients receiving Pembrolizumab as adjuvant therapy</description>
        <time_frame>until death, withdrawal of consent of end of the study. as such, we have not reached the median DFS and will report at the end of the study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>All SAEs are reported. Grade 3-5 AEs and SAEs and occurring in at least 5% of subjects are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neo-adjuvant/Adjuvant Pembrolizumab 200mg IV</title>
          <description>Pembrolizumab 200 mg: Subjects received 1 dose of neoadjuvant pembrolizumab, followed by complete resection, and then a year of adjuvant pembrolizumab.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>esophageal obstruction</sub_title>
                <description>Grade 3 unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <description>Grade 3 unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <description>Grade 3 possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>grade 3 enteritis possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>wound infection</sub_title>
                <description>grade 3 unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <description>grade 4 unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Grade 3 rash</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tara Mitchell</name_or_title>
      <organization>Abramson Cancer Center</organization>
      <phone>215-662-7908</phone>
      <email>tara.mitchell@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

